Partnerships

Corporate Partnerships, Collaborations and Licensing Agreements

At BioTime, we are committed to discovering, developing and delivering innovative therapies for age-related degenerative diseases for which no cures currently exist. A key part of achieving that goal is the formation of strategic alliances, licensing arrangements, partnerships, and collaborations. Over the years, we have forged a number of valuable relationships, including the following:


 


Beckman Research Institute of City of Hope

BioTime company ES Cell International Pte. Ltd. BioTime Licensed Beckman Research Institute of City of Hope to Manufacture Clinical Grade […]

Read More

Mount Sinai – National Jewish Health Respiratory Institute

BioTime company LifeMap Solutions collaborated with the Icahn School of Medicine at Mount Sinai and National Jewish Health Respiratory Institute […]

Read More

GE Healthcare

BioTime Subsidiary ES Cell International and GE Healthcare Cross-License Patents in the Field of Cell Assays for Drug Testing

Read More

Heraeus Medical GmbH

BioTime’s subsidiary OrthoCyte Corporation and Heraeus Medical have entered into exclusive development and worldwide licensing agreements for the development of […]

Read More

Abcodia Ltd.

BioTime company OncoCyte entered into a collaboration with Abcodia Ltd., a UK-based company focused on early detection of cancer, to […]

Read More

Cancer Research UK

BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for […]

Read More

University of Wisconsin and Louvain University

BioTime entered into a collaboration with the University of Wisconsin and Louvain University in Belgium to evaluate BioTime’s proprietary HyStem®-based […]

Read More

California Institute of Regenerative Medicine

BioTime company Asterias Biotherapeutics (NYSE MKT: AST) was granted a $14.3 million Strategic Partnership Award by the California Institute for […]

Read More

Cornell University

BioTime company OncoCyte signed a license agreement with Cornell University through which Cornell’s Weill Cornell Medical College will provide blood […]

Read More

EyeGate, formerly Jade Therapeutics

BioTime signed an exclusive sublicense agreement with Jade Therapeutics, a developer of ophthalmic sustained-release drug delivery platforms for use of […]

Read More

University of California, Los Angeles

BioTime formed an exclusive license agreement with the University of California to develop a therapy for the treatment of stroke.

Read More